Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK536692PMID: 30694624
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2055491-00-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of tagraxofusp during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during tagraxofusp therapy and for 1 week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tagraxofusp
CAS Registry Number
2055491-00-2
Drug Class
- Breastfeeding
- Antineoplastic Agents
- Recombinant Fusion Proteins
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Binimetinib.[Drugs and Lactation Database (...]Review Binimetinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.[Expert Rev Anticancer Ther. 2020]Review Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.Lee SS, McCue D, Pemmaraju N. Expert Rev Anticancer Ther. 2020 Jul; 20(7):543-550. Epub 2020 Jun 24.
- Review Ribociclib.[Drugs and Lactation Database (...]Review Ribociclib.. Drugs and Lactation Database (LactMed®). 2006
- Review Brigatinib.[Drugs and Lactation Database (...]Review Brigatinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.[Drugs Today (Barc). 2019]Review Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.Tandon A, Zhang Y, Sokol L. Drugs Today (Barc). 2019 Dec; 55(12):735-742.
- Tagraxofusp - Drugs and Lactation Database (LactMed®)Tagraxofusp - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...